Form 8-K - Current report:
SEC Accession No. 0001193125-25-033539
Filing Date
2025-02-24
Accepted
2025-02-24 17:22:19
Documents
17
Period of Report
2025-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d921088d8k.htm   iXBRL 8-K 29006
2 EX-1.1 d921088dex11.htm EX-1.1 204839
3 EX-5.1 d921088dex51.htm EX-5.1 10656
7 GRAPHIC g921088g0221015954221.jpg GRAPHIC 2529
8 GRAPHIC g921088g0221020136082.jpg GRAPHIC 28104
  Complete submission text file 0001193125-25-033539.txt   469236

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fgen-20250224.xsd EX-101.SCH 2853
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fgen-20250224_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fgen-20250224_pre.xml EX-101.PRE 11263
20 EXTRACTED XBRL INSTANCE DOCUMENT d921088d8k_htm.xml XML 3656
Mailing Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133
Business Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133 415-978-1200
FIBROGEN INC (Filer) CIK: 0000921299 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36740 | Film No.: 25658262
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)